Preview

Медицинский Совет

Расширенный поиск

Корифоллитропин альфа. Эффективность, безопасность и комфортность для врача и пациента

https://doi.org/10.21518/2079-701X-2016-2-42-49

Полный текст:

Аннотация

Проведен анализ сравнения эффективности и безопасности единственного на сегодня препарата корифоллитропина альфа по сравнению с препаратами рекомбинантного фолликулостимулирую-щего гормона (рФСГ), назначаемыми с целью стимуляции мультифолликулярного роста в рамках методов экстракорпорального оплодотворения/интрацитоплазматической инъекции сперматозоида в яйцеклетку. По результатам многочисленных источников сделан вывод о сравнимой эффективности в отношении частоты живорождения, клинической и прогрессирующей беременности между пациентками, применявшими корифоллитропин альфа, и пациентками, применявшими рФСГ в течение первых 7 дней стимуляции. Не выявлено статистической разницы между группами препаратов корифоллитропина альфа и рФСГ в отношении частоты эктопической и многоплодной беременности, риска развития СГСЯ, развития пороков эмбриона/плода. Не обнаружено клинически весомой частоты образования антител к корифоллитропину альфа. Выявлены статистические различия в выраженности овариального ответа между группами пациенток, применявших корифоллитропин альфа, и пациенток, применявших препараты рФСГ, выражающиеся в большем количестве получаемых комплексов ооцит-кумулус в группе корифоллитропин альфа. Показана большая удовлетворенность пациентов от приема корифоллитропина альфа по сравнению с препаратами рФСГ за счет снижения количества необходимых инъекций.

Об авторах

Э. Ш. Абляева
Клиника «Мать и дитя»
Россия


И. А. Бендусов
Клиника «Мать и дитя»
Россия


Список литературы

1. Schroder AK, KataLinic A, Diedrich K, Ludwig M. Cumulative pregnancy rates and drop-out rates in a German IVF programme: 4102 cycles in 2130 patients. Reproductive Biomedicine Online, 2004, 8(5): 600-6.

2. Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, de KLerk C, Fauser BC, MackLon NS. Why do couples drop-out IVF treatment? A prospective cohort stady. Hum Reprod, 2008 Sep, 23(9): 2050-5. doi: 10.

3. L. van den Wijngaard, ICM Rodijk, F van der Veen, MHW Gooskens-van Erven, CAM Koks, HR Verhoeve, BWJ. MoL, M van WeLy, and MH Mochtar. Patient preference for a Long-acting recombinant FSH product in ovarian hyper-stimuLation in IVF: a discrete choice experiment. Hum Reprod, 2015 Feb, 30(2): 331-7. doi: 10.1093/humrep/deu307. Epub 2014 Nov 28.

4. Jacky Boivin, Lena Andersson, Agneta Skoog-Svanberg, Anna HjeLmstedt, AiLa CoLLins, Torbjorn Bergh. PsychoLogicaL reactions during in-vitro fertiLization: simiLar response pattern in husbands and wives. Hum Reprod, 1998 Nov, 13(11): 3262-7.

5. M Brandes, JOM van der Streen, SB Bokdam, CJCM HamiLton, JP de Bruin, WLDM NeLen, JAM Kremer. When and why do subfertiLe coupLes discontinue their fertiLity care? A LongitudinaL cohort study in a secondary care subfertiLity popuLation. Hum Reprod, 2009 Dec, 24(12): 3127-35. doi: 10.1093/ humrep/dep340. Epub 2009 Sep 26.

6. Ashraf Moini, Sahar SaLehizadeh, Farzaneh Moosavi, Kiandokht Kiani, Soraya Khafri. Discontinuation Decision in Assisted Reproductive Techniques. Hum Reprod Update, 2012 Nov, 18(6): 652-669. PubLished onLine 2012 Aug 6. doi: 10.1093/humupd/dms031.

7. S Gameiro, J Boivin, L Peronace and CM Verhaak. Why do patients discontinue fertiLity treatment? A systematic review of reasons and predictors of discontinuation in fertiLity treatment. Hum Reprod Update, 2012 Nov,18(6): 652669. PubLished onLine 2012 Aug 6. doi: 10.1093/humupd/dms031.

8. Fares FA, Suganuma N, Nishimori K, LaPoLt PS, Hsueh AJ, Boime I. Design of a Long-acting foL-Litropin agonist by fusing the C-terminaL sequence of the chorionic gonadotropin beta subunit to the foLLitropin beta subunit. Proc Natl Acad Sci U S A, 1992, 89(10): 4304-4308.

9. Strauss JF III, Barbieri R. Yen and Jaffe's Reproductive EndocrinoLogy: PhysioLogy, PathophysioLogy, and CLinicaL Management. 5th ed. PhiLadeLphia, PA: Saunders, 2004.

10. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technoLogy: corifoLLitropin aLfa, a hybrid moLecuLe with sustained foLLicLe-stimuLating activity and reduced injection frequency. Hum Reprod Update, 2009, 15: 309-21.

11. Devroey P, Boostanfar R, Koper NP et aL. A doubLe-bLind, non-inferiority RCT comparing cori-foLLitropin aLfa and recombinant FSH during the first seven days of ovarian stimuLation using a GnRH antagonist protocoL. Hum Reprod, 2009, 24(12): 3063-3072.

12. BouLoux PM, HandeLsman DJ, JockenhoveL F, et aL. First human exposure to FSH-CTP in hypog-onadotrophic hypogonadaL maLes. Hum Reprod, 2001, 16(8): 1592-1597.

13. Duijkers Ij, KLipping C, Boerrigter PJ et aL. SingLe dose pharmacokinetics and effects on foLLicuLar growth and serum hormones of a Long-acting recombinant FSH preparation (FSH-CTP) in heaLthy pituitary-suppressed femaLes. Hum Reprod, 2002, 17(8): 1987-1993.

14. BaLen AH, MuLders AG, Fauser BC, et aL. Pharmacodynamics of a singLe Low dose of Longacting recombinant foLLicLe-stimuLating hormone (FSH-carboxy terminaL peptide, cori-foLLitropin aLfa) in women with WorLd HeaLth Organization group II anovuLatory infertiLity. J Clin Endocrinol Metab., 2004, 89(12): 6297-6304.

15. de Greef R, ZandvLiet AS, de Haan Af, et aL. Dose seLection of corifoLLitropin aLfa by modeLing and simuLation in controLLed ovarian stimuLation. Clin Pharmacol Ther., 2010, 88(1): 79-87.

16. ScheLLekens H. BioequivaLence and the immu-nogenicity of biopharmaceuticaLs. Nat Rev Drug Discov., 2002 Jun, 1(6): 457-62.

17. Norman RJ, Zegers-HochschiLd F, SaLLe BS, et aL. Repeated ovarian stimuLation with corifoLLitro-pin aLfa in patients in a GnRH antagonist protocoL: no concern for immunogenicity. Hum Reprod, 2011, 26(8): 2200-2208.

18. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ljzerman-Boon PC, Fauser BC. A doubLe-bLind, non-inferiority RCT comparing corifoLLitropin aLfa and recombinant FSH during the first seven days of ovarian stimuLation using a GnRH antagonist protocoL&. Hum Reprod, 2009, 24: 3063-72. Corrigendum: Hum Reprod, 2014, 29: 1116-20.

19. Boostanfar R, Yeko T, Shapiro B, ELbers J, Witjes H, Mannaerts B. A Large doubLe-bLind efficacy and safety triaL of corifoLLitropin aLfa versus daiLy recombinant FSH in women 35 to 42 years of age undergoing ovarian stimuLation prior to IVF or ICSI (pursue triaL). Fertility and Sterility, 2012, 98(SuppL 1): S34.

20. Fauser BC, ALper MM, Ledger W, SchooLcraft WB, ZandvLiet A, Mannaerts BM, Engage Investigators. Pharmacokinetics and foLLicuLar dynamics of cori-foLLitropin aLfa versus recombinant FSH during ovarian stimuLation for IVF. Reproductive BioMedicine Online, 2010, 21(5): 593-601.

21. Devroey P, Fauser BC, PLatteau P et aL. Induction of muLtipLe foLLicuLar deveLopment by a singLe dose of Long-acting recombinant foLLicLe-stimuLating hormone (FSH-CTP, corifoL-Litropin aLfa) for controLLed ovarian stimuLation before in vitro fertiLization. J Clin Endocrinol Metab., 2004, 89(5): 2062-2070.

22. CorifoLLitropin ALfa Dose-finding Study Group: AbyhoLm T, Andersen AN, BaLen AH, Braat DD, Devroey P, D'Hooghe TH, FeLberbaum R, Fauser BJ, Fridstrom M, HiLLensjo T, Keck C, Kurunmaki H, Lindenberg S, OmbeLet W, Tapanainen J, VariLa E, Wramsby H, Koper NP, de Haan AF, Struys MJ. A randomized dose-response triaL of a singLe injection of corifoLLitropin aLfa to sustain muLti-foLLicuLar growth during controLLed ovarian stimuLation. Hum Reprod, 2008 Nov, 23(11): 2484-92. doi: 10.1093/humrep/den288. Epub 2008 Aug 6.

23. CorifoLLitropin aLfa Ensure Study Group: Obruca A, Schenk M, Tews G, Mardesic T, Mrazek M, Meinertz H, Hedon B, Barriere P, Kim C, Koong M, Yoon T, KozioL K, Kuczynski W, Bernabeu R, BaLda JA, Bergh C, HiLLensjo T, Huang HY, Yang YS, von Mauw E, ELbers J, Witjes H, ZandvLiet AS, Mannaerts B. CorifoLLitropin aLfa for ovarian stimuLation in IVF: a randomized triaL in Lower-body-weight women. Reprod Biomed Online, 2010 JuL, 21(1): 66-76. doi: 10.1016/j. rbmo.2010.03.019. Epub 2010 Mar 28.

24. V SiouLas, C Siristatidis, C ChreLias, E ALexiou, T Vrantza, D Kassanos. CorifoLLitropin aLfa vs. recombinant foLLicLe stimuLating hormone in ovarian stimuLation of women undergoing in vitro fertiLization: preLiminary resuLts. Fertility and Sterility, 2011, 96, 3: S181.

25. AnnefLoor W Power, Cindy Farquhar, Jan AM Kremer. Long-acting FSH versus daiLy FSH for women undergoing assisted reproduction (Review). Copyring©2015. The Cochrane Collaboration. PubLished by John WiLey & Sons, Ltd.

26. Stefania Fensore, Marco Di Marzio and Gian Mario Tiboni. CorifoLLitropin aLfa compared to daiLy FSH in controLLed ovarian stimuLation for in vitro fertiLization: a meta-anaLysis. Journal of Ovarian Research, 2015 Jun 3, 8: 33. doi: 10.1186/s13048-015-0160-4.

27. Mohamed AbdeLfattah Mahmoud Youssef, MadeLon van WeLy, IsmaiL AbouLfoutouh, WaLid EL-Khyat, FuLco van der Veen, Hesham AL-Inany. Is there a pLace for corifoLLitropin aLfa in IVF/ICSI cycLes? A systematic review and meta-anaLysis. Fertil Steril, 2012 Apr, 97(4): 876-85. doi: 10.1016/j. fertnstert.2012.01.092. Epub 2012 Jan 23.

28. NikoLaos P PoLyzos, MicheL Camus, Joaquin LLacer, Konstantinos Pantos, Herman Tournaye. CorifoLLitropin a foLLowed by menotropin for poor ovarian responders' triaL (COMPORT): a protocoL of a muL-ticentre randomised triaL. BMJ Open, 2013, 3: e002938. doi:10.1136/bmjopen-2013-002938.

29. Kevin J Doody, PauL Devroey, Arthur Leader, Han Witjes, Bernadette M Mannaerts. No association between endogenous LH and pregnancy in a GnRH antagonist protocoL: part I, corifoLLitropin aLfa. Reprod Biomed Online, 2011 Oct, 23(4): 449-56. doi: 10.1016/j.rbmo.2011.06.015. Epub 2011 JuL 7

30. C BLockeeL, NP PoLyzos, L Derksen, M De Brucker, V VLoeberghs, A van de Vijver, M De Vos and H Tournaye. Administration of corifoLLitropin aLfa on Day 2 versus Day 4 of the cycLe in a GnRH antagonist protocoL: A randomized controLLed piLot study. Hum Reprod, 2014 JuL, 29(7): 1500-7. Epub 2014 May 9.

31. ALberto ReveLLi & GiuLia Pittatore & Simona Casano & Stefano Canosa & Francesca EvangeLista & Chiara Benedetto. Efficacy and safety of Late-start CorifoLLitropin-aLfa administration for controLLed ovarian hyperstimuLation in IVF: a cohort, case-controL study. J Assist Reprod Genet, 2015 Mar, 32(3): 429-34. doi: 10.1007/s10815-014-0426-6. Epub 2015 Jan 15.

32. EM KoLibianakis, CA Venetis, JK Bosdou, L Zepiridis, K ChatzimeLetiou, A Makedos, S Masouridou, S TriantafiLLidis, A MitsoLi and BC TarLatzis. CorifoLLitropin aLfa compared with foL-Litropin beta in poor responders undergoing ICSI: a randomized controLLed triaL. Hum Reprod, 2015 Feb, 30(2): 432-40. doi: 10.1093/humrep/ deu301. Epub 2014 Dec 9.

33. NikoLaos P PoLyzos, Herman Tournaye, Luis Guzman, MicheL Camus, Scott M NeLson. Predictors of ovarian response in women treated with corifoLLitropin aLfa for in vitro fertiLiza-tion/intracytopLasmic sperm injection. Fertil Steril, 2013 Aug, 100(2): 430-7. doi: 10.1016/j. fertnstert.2013.04.029. Epub 2013 May 10.

34. Габараева В.В., Калугина А.С. Сравнительная эффективность препарата корифоллитропин-альфа в программе донорства ооцитов. Проблемы репродукции, 2015, 21(5): 58-62. doi: 10.17116/repro201521558-62.

35. Antonio Requena, Mar' ia Cruz, Diana CoLLado, ALexandra Izquierdo, Agust' in BaLLesteros, Manue! Mun~oz, Juan Antonio Garc' la-VeLasco. EvaLuation of the degree of satisfaction in oocyte donors using sustained-reLease FSH corifoLLitropin a. Reprod Biomed Online, 2013 Mar, 26(3): 253-9. doi: 10.1016/j.rbmo.2012.11.015. Epub 2012 Dec 5.

36. Gabaraeva V.V., Kalugina A.S. Comparative efficacy of corifollitropin-alpha in the oocyte donation program. Problemy Reproduktsii, 2015, 21(5): 58-62. doi: 10.17116/repro201521558-62.


Просмотров: 172


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)